Back to top
more

Corbus Pharmaceuticals (CRBP)

(Delayed Data from NSDQ)

$9.11 USD

9.11
93,292

+0.21 (2.36%)

Updated Aug 6, 2025 04:00 PM ET

After-Market: $9.06 -0.05 (-0.55%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value F Growth C Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 34% (83 out of 246)

Industry: Medical - Drugs

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Corbus Pharmaceuticals (CRBP) Expected to Beat Earnings Estimates: Should You Buy?

by Zacks Equity Research

Corbus Pharmaceuticals (CRBP) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Corbus Stock Down as Lenabasum Fails to Meet Primary Endpoint

by Zacks Equity Research

Corbus (CRBP) releases disappointing top-line results from its 28-week phase IIb study of lenabasum in patients with cystic fibrosis.

Zacks Equity Research

Are Options Traders Betting on a Big Move in Corbus (CRBP) Stock?

by Zacks Equity Research

Investors need to pay close attention to Corbus (CRBP) stock based on the movements in the options market lately.

Zacks Equity Research

Implied Volatility Surging for Corbus Pharmaceuticals (CRBP) Stock Options

by Zacks Equity Research

Investors need to pay close attention to Corbus Pharmaceuticals (CRBP) stock based on the movements in the options market lately.

Zacks Equity Research

Are Options Traders Betting on a Big Move in Corbus Pharmaceuticals (CRBP) Stock?

by Zacks Equity Research

Investors need to pay close attention to Corbus Pharmaceuticals (CRBP) stock based on the movements in the options market lately.

Zacks Equity Research

Is the Options Market Predicting a Spike in Corbus Pharmaceuticals (CRBP) Stock?

by Zacks Equity Research

Investors need to pay close attention to Corbus Pharmaceuticals (CRBP) stock based on the movements in the options market lately.

Zacks Equity Research

Is Corbus Pharmaceuticals (CRBP) Stock a Solid Choice Right Now?

by Zacks Equity Research

Corbus Pharmaceuticals (CRBP) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

Zacks Equity Research

Corbus Pharmaceuticals (CRBP) Moves to Buy: Rationale Behind the Upgrade

by Zacks Equity Research

Corbus Pharmaceuticals (CRBP) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Zacks Equity Research

Do Options Traders Know Something About Corbus Pharmaceuticals (CRBP) Stock We Don't?

by Zacks Equity Research

Investors need to pay close attention to Corbus Pharmaceuticals (CRBP) stock based on the movements in the options market lately.

Zacks Equity Research

Corbus Pharmaceuticals (CRBP) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

Corbus Pharmaceuticals (CRBP) delivered earnings and revenue surprises of 0.00% and 7.44%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Implied Volatility Surging for Corbus (CRBP) Stock Options

by Zacks Equity Research

Investors need to pay close attention to Corbus (CRBP) stock based on the movements in the options market lately.

Zacks Equity Research

Corbus Pharmaceuticals (CRBP) Reports Q4 Loss, Lags Revenue Estimates

by Zacks Equity Research

Corbus Pharmaceuticals (CRBP) delivered earnings and revenue surprises of -20.59% and -44.55%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Earnings Preview: Corbus Pharmaceuticals (CRBP) Q4 Earnings Expected to Decline

by Zacks Equity Research

Corbus Pharmaceuticals (CRBP) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Are Options Traders Betting on a Big Move in Corbus Pharmaceuticals (CRBP) Stock?

by Zacks Equity Research

Investors need to pay close attention to Corbus Pharmaceuticals (CRBP) stock based on the movements in the options market lately.

Zacks Equity Research

Corbus Pharmaceuticals (CRBP) Reports Q3 Loss, Tops Revenue Estimates

by Zacks Equity Research

Corbus Pharmaceuticals (CRBP) delivered earnings and revenue surprises of 11.11% and 49.71%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Corbus Pharmaceuticals (CRBP) Q2 Earnings and Revenues Beat Estimates

by Zacks Equity Research

Corbus Pharmaceuticals (CRBP) delivered earnings and revenue surprises of 113.64% and 181.93%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Kadmon Initiates Dosing in Study for Systemic Sclerosis Drug

by Zacks Equity Research

Kadmon (KDMN) doses first patient in a phase II study of KD025 for the treatment of diffuse cutaneous systemic sclerosis (SSc).

Zacks Equity Research

Corbus Pharmaceuticals (CRBP) Reports Q1 Loss, Lags Revenue Estimates

by Zacks Equity Research

Corbus Pharmaceuticals (CRBP) delivered earnings and revenue surprises of -2250.00% and -91.01%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

What's in the Cards for Corbus (CRBP) This Earnings Season?

by Zacks Equity Research

Corbus (CRBP) will provide updates on its lead candidate lenabasum, when it releases first-quarter 2019 results.

Zacks Equity Research

What's in Store for Sorrento (SRNE) This Earnings Season?

by Zacks Equity Research

Sorrento (SRNE) may provide update on progress of ZTlido on the first quarter earnings call.

Zacks Equity Research

Corbus Pharmaceuticals (CRBP) to Report Q1 Results: Wall Street Expects Earnings Growth

by Zacks Equity Research

Corbus Pharmaceuticals (CRBP) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

What's in Store for BioDelivery (BDSI) This Earnings Season?

by Zacks Equity Research

Investor focus will be on the performance of BioDelivery Sciences' (BDSI) two marketed drugs, Belbuca (chronic pain) and Bunavail (opioid-dependence).

Zacks Equity Research

What's in the Cards for AEterna (AEZS) This Earnings Season?

by Zacks Equity Research

AEterna (AEZS) may provide update on the path forward for Macrilen in Europe on the first-quarter earnings call.

Zacks Equity Research

What's in the Cards for Zynerba (ZYNE) This Earnings Season?

by Zacks Equity Research

Zynerba Pharmaceuticals' (ZYNE) operating expenses are expected to be higher in the first quarter due to clinical studies on its lead pipeline candidate, Zygel.

Zacks Equity Research

All You Need to Know About Corbus Pharmaceuticals (CRBP) Rating Upgrade to Buy

by Zacks Equity Research

Corbus Pharmaceuticals (CRBP) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.